摘要
目的 探究术前TEC化疗联合保乳病灶切除术治疗Ⅱb~Ⅲb期乳腺癌患者的疗效及安全性.方法 选取2018年1月~2019年10月接收的Ⅱb~Ⅲb期乳腺癌患者92例,随机数字表法分为观察组(n=46)和对照组(n=46),对照组采用改良根治术联合术后TEC化疗,观察组采用术前TEC化疗联合保乳病灶切除术治疗.比较两组手术相关指标(手术时间、术中出血量、住院天数)、临床疗效、术后并发症情况、复发率.结果 观察组手术时间、住院天数短于对照组,术中出血量低于对照组(P<0.05);观察组优良率91.30% 高于对照组58.70%(P<0.05);观察组并发症发生率8.70% 低于对照组26.09%(P<0.05);术后随访6个月,观察组复发率8.89%(4/45)与对照组11.36%(5/44)相比无显著差异(P>0.05).结论 术前TEC化疗联合保乳病灶切除术可有效缩短手术时间,减少术中出血量,加快术后康复进程,且术后并发症少,是治疗Ⅱb~Ⅲb期乳腺癌患者有效方案.
Objective To investigate the efficacy and safety of preoperative TEC chemotherapy combined with breast-conserving lesion resection for patients with stageⅡb~Ⅲb breast cancer.Methods A total of 92 patients with stageⅡb~Ⅲb breast cancer received from January 2018 to October 2019 were selected and divided into an observation group(n=46)and a control group(n=46)by random number table method.the control group was treated with modified radical mastectomy combined with postoperative TEC chemotherapy,and the observation group was treated with preoperative TEC chemotherapy combined with breast-conserving lesion resection.The operation-related indicators(operation time,intraoperative blood loss,hospitalization days),clinical efficacy,postoperative complications and recurrence rate of the two groups were compared.Results The operation time and hospital stay in the observation group were shorter than those in the control group,and the intraoperative blood loss was lower than that in the control group(P>0.05).The excellent rate of 91.30%in the observation group was higher than 58.70%in the control group(P>0.05).The incidence of complications in the observation group was 8.70%lower than that in the control group at 26.09%(P>0.05).After 6 months of follow-up,there was no significant difference in the relapse rate of 8.89%(4/45)in the observation group and 11.36%(5/44)in the control group(P>0.05).Conclusion Preoperative TEC chemotherapy combined with breast-conserving lesion resection can effectively shorten the operation time and reduce the amount of intraoperative bleeding,it can accelerate the postoperative recovery process and has fewer postoperative complications,it is an effective solution for patients with stageⅡb~Ⅲb breast cancer.
作者
桑晓旻
SANG Xiao-min(Department of surgery,Tianjin jinnan hospital,Tianjin 300052,China.)
出处
《中国处方药》
2020年第8期130-132,共3页
Journal of China Prescription Drug
关键词
保乳病灶切除术
乳腺癌
安全性
并发症
Breast-conserving lesion resection
Breast cancer
Safety
Complications
